Associations of the uric acid related genetic variants in SLC2A9 and ABCG2 loci with coronary heart disease risk

Xu Han¹, Lixuan Gui¹, Bing Liu¹, Jing Wang¹, Yaru Li¹, Xiayun Dai¹, Jun Li¹, Binyao Yang¹, Gaokun Qiu¹, Jing Feng¹, Xiaomin Zhang¹, Tangchun Wu¹ and Meian He¹²*

Abstract

Background: Multiple studies investigated the associations between serum uric acid and coronary heart disease (CHD) risk. However, further investigations still remain to be carried out to determine whether there exists a causal relationship between them. We aim to explore the associations between genetic variants in uric acid related loci of SLC2A9 and ABCG2 and CHD risk in a Chinese population.

Results: A case–control study including 1,146 CHD cases and 1,146 controls was conducted. Association analysis between two uric acid related variants (SNP rs11722228 in SLC2A9 and rs4148152 in ABCG2) and CHD risk was performed by logistic regression model. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Compared with subjects with A allele of rs4148152, those with G allele had a decreased CHD risk and the association remained significant in a multivariate model. However, it altered to null when BMI was added into the model. No significant association was observed between rs11722228 and CHD risk. The distribution of CHD risk factors was not significantly different among different genotypes of both SNPs. Among subjects who did not consume alcohol, the G allele of rs4148152 showed a moderate protective effect. However, no significant interactions were observed between SNP by CHD risk factors on CHD risk.

Conclusions: There might be no association between the two uric acid related SNPs with CHD risk. Further studies were warranted to validate these results.

Keywords: Coronary heart disease, Uric acid, Polymorphism, Gene-environment interaction

Background

Coronary heart disease (CHD) is one of the leading causes of morbidity and mortality throughout the world [1]. The World Health Organization estimated that each year more than 700,000 people die from CHD in China with a substantial economic burden [2]. CHD is a multifactorial disease resulting from genetic, environmental factors and their interaction [3]. Known risk factors for CHD include obesity, smoking, diabetes, dislipidemia and etc. [4–7].

Uric acid, as the end product of purine metabolism, is a major cause of gout [8,9]. Studies indicated that uric acid levels were associated with insulin resistance [10] and metabolic syndromes [11]. In addition, epidemiological studies have investigated the association of uric acid levels with CHD risk with inconsistent results [4,12–19]. Some studies found uric acid levels were positively associated with CHD risk [4,13,14,20]. In contrast, some studies found no association between them [21,22]. Similar controversial findings were found in Chinese population [23–25]. Therefore, it still remains to be investigated whether there is a causal association between serum uric acid levels and CHD risk.

Recent genome-wide association studies (GWASs) identified multiple genetic loci associated with serum uric acid concentrations [9,13,18,26,27]. Our previous GWAS also
confirmed two reported loci SLC2A9 (solute carrier family 2, facilitated glucose transporter member 9, 4p16.1) [18,22,26,28,29] and ABCG2 (ATP-binding cassette, sub-family G, member 2, 4q22) [12,30,31] positively associated with serum uric acid levels in a Chinese population [32]. Several studies investigated the associations between the genetic variants in the uric acid related loci of SLC2A9 and ABCG2 and the risk of CHD among Europeans [12,22,25,33,34] and found no association between them. It is necessary to further investigate their associations among other populations.

In the present study, a case–control design (consisting of 1,146 cases with 1,146 age- and sex-frequency matched controls) was adopted and two SNPs rs11722228 (intron in SLC2A9) and rs4148152 (intron in ABCG2), which were in the previously reported uric acid related loci and confirmed in our GWAS [32,35,36], were selected to examine their associations with the CHD risk among Chinese. To our best knowledge, there were no studies investigating the association of these two SNPs and CHD risk before. The results in the present study will help us to verify the existence of causal relationship between serum uric acid levels and CHD risk.

Methods

Study population

The subjects included in the present study were recruited consecutively at the department of cardiology from three hospitals (Tongji Hospital, Union Hospital, and Wugang Hospital) in Wuhan city (Hubei province, China) between May 2004 and October 2006. Quantitative coronary angiography was performed by experienced cardiologists who had no knowledge of the patients’ clinical information. After exclusion of those who had acute renal and liver diseases or with incomplete information, 2,292 individuals of 1,146 cases with 1,146 age- and sex-frequency matched controls were included in our study. All the subjects were unrelated Chinese Han individuals and lived in Hubei province, the central China. The baseline characteristics of cases and controls were shown in Table 1. Our study has been approved by the Medical Ethics Committee of the School of Public Health, Tongji Medical College. Written informed consents were obtained from all the participants.

Data collection

General health examination was performed including standing height and body weight. Height was measured to the nearest 0.01 cm with subjects standing without shoes. Weight was measured using a digital scale with subjects wearing light clothing and recorded to the nearest 0.1 kg. Body mass index (BMI) was calculated as body weight in kilograms divided by standing height in meters squared [7,37]. Those who had smoked more than 100 cigarettes in lifetime were defined as smokers; otherwise, they were defined as nonsmokers. Subjects were considered hypertensive as blood pressure ≥140/90 mmHg or they were treated with antihypertensive medications. Diabetes mellitus was defined either by the World Health Organization criteria or by self-report of being previously diagnosed as diabetes [38]. Family history was positive if first-degree relatives had CHD [39].

Table 1 Baseline characteristics of the CHD case and control subjects

| Variables             | CHD cases (n = 1,146) | Control subjects (n = 1,146) | P value |
|-----------------------|-----------------------|-----------------------------|---------|
| Age (years)           | 60.0 ± 10.3           | 60.5 ± 11.3                  | 0.229   |
| Gender (male/female)  | 891/255 (77.7/22.3)   | 901/245 (78.6/21.4)          | 0.613   |
| BMI (kg/m²)           | 24.4 ± 3.3            | 23.7 ± 3.1                   | <0.01   |
| Smoking, no/yes, (%)  | 774/369 (66.7/32.3)   | 686/460 (59.9/40.1)          | <0.01   |
| Drinking, no/yes, (%) | 822/317 (72.2/27.8)   | 776/365 (68.0/32.0)          | <0.01   |
| Systolic blood pressure (mmHg) | 136.0 ± 25.3         | 133.6 ± 29.0                 | 0.034   |
| Diastolic blood pressure (mmHg) | 82.9 ± 15.2          | 82.0 ± 11.3                  | 0.110   |
| Fasting blood glucose (mmol/L) | 6.2 ± 3.0            | 5.6 ± 2.2                    | <0.01   |
| Total cholesterol (mmol/L) | 4.4 ± 1.1            | 4.7 ± 0.9                    | <0.01   |
| Triglyceride (mmol/L)  | 1.7 ± 1.4            | 1.6 ± 1.3                    | 0.283   |
| HDL cholesterol (mmol/L) | 1.2 ± 0.7            | 1.1 ± 0.4                    | <0.01   |
| LDL cholesterol (mmol/L) | 2.6 ± 0.9            | 2.7 ± 0.8                    | <0.01   |
| Past history          |                       |                             |         |
| Diabetes, no/yes, (%) | 824/314 (72.4/27.6)   | 1080/65 (94.3/5.7)           | <0.01   |
| Hypertension, no/yes, (%) | 351/790 (30.8/69.2) | 784/361 (68.5/31.5)         | <0.01   |
| Family history of CHD, no/yes, (%) | 947/158 (85.7/14.3) | 1133/10 (99.1/0.9) | <0.01   |

Values are mean ± SD, n (%) or as indicated. CHD: coronary heart disease; BMI: body mass index; HDL: high density lipoprotein; LDL: low density lipoprotein.
Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride levels were assayed according to standard laboratory procedures in the Department of Clinical Laboratory at Union Hospital and Tongji Medical College.

Definition of coronary heart disease
The diagnostic criteria for CHD cases included one of the followings: (1) presence of a stenosis > 50% in at least one of the major segments of coronary arteries (right coronary artery, left circumflex, or left anterior descending arteries) based on coronary angiography, which can be seen in more details in previous studies [6,40,41]; (2) according to the World Health Organization criteria in terms of elevated cardiac enzymes, changes in electrocardiography and clinical symptoms; (3) a documented history of coronary artery bypass graft or percutaneous coronary intervention. Patients with congenital heart disease, cardiomyopathy, or severe vascular disease were excluded. All control subjects were determined to be free of CHD and peripheral atherosclerotic arterial diseases according to medical history, clinical examinations and electrocardiography. The controls were recruited in a population-based survey and resided in the same communities as the cases.

Genotyping
Venous blood samples were collected after a 12 h overnight fasting and were drawn within 2 vacuum (ethylendiamine tetraacetic acid, EDTA) anticoagulation tubes for plasma and DNA. The blood specimens were frozen in −80°C until assayed. Genomic DNA was isolated with a Puregene kit (Gentra Systems, Inc., Minneapolis, MN, USA).

Two SNPs rs11722228 (SLC2A9) and rs4148152 (ABCG2), which were associated with uric acid levels in our recent GWAS [32], were selected and genotyped with the Sequenom MassARRAY iPLEX platform (Sequenom, Inc. San Diego, CA, USA) in 384-well format. The call rate was 97.6% and 97.1% for rs11722228 and rs4148152, respectively. In addition, we re-genotyped 5% of the total frequency of SNP rs11722228 in controls was 52.7%, 40.3%, and 9.9%. In cases it was 47.4%, 42.0%, and 7.8%. In controls, the genotype frequency of AA, AG, and GG was 42.6%, and 10.0%, respectively. No significant difference of the genotype frequency of rs11722228 was observed between the CHD group and the control group. SNP rs11722228 was not significantly associated with CHD risk. In contrast, the rs4148152-AG genotype had a significantly decreased risk of CHD (age and sex adjusted OR = 0.78, 95% CI: 0.66-0.93; P = 0.006) and the association stayed significant in a multivariate model (adjusted

Results
Baseline characteristics analysis between cases and controls
In the present case–control study, CHD controls (n = 1,146) were frequency matched for age and sex to cases (n = 1,146). Baseline characteristics of study individuals are shown in Table 1. Compared with the control group, CHD cases were more likely to have significantly higher BMI, systolic blood pressure, fasting glucose, and HDL cholesterol levels (all P < 0.05). However, the levels of TC and LDL cholesterol were significantly lower in cases than those in controls, which might be due to the intake of cholesterol-lowering medications in CHD cases. The percentage of past history of diabetes and hypertension, and family history of CHD in cases were dramatically higher in contrast to that in control subjects (all P < 0.01).

Associations of uric acid levels related SNPs with CHD risk
As shown in Table 2, the CC, CT, and TT genotype frequency of SNP rs11722228 in controls was 52.7%, 40.3%, and 7.0%. It was 50.2%, 42.0%, and 7.8% in the CHD group, respectively. The frequency of the C and T allele was not significantly different between the CHD group and the control group. For the SNP rs4148152, the genotype frequency of AA, AG, and GG in the controls was 42.0%, 48.1%, and 9.9%. In cases it was 47.4%, 42.6%, and 10.0%, respectively. No significant difference of the genotype frequency of rs4148152 was observed between the CHD group and the control group. SNP rs11722228 was not significantly associated with CHD risk. In contrast, the rs4148152-AG genotype had a significantly decreased risk of CHD (age and sex adjusted OR = 0.78, 95% CI: 0.66-0.93; P = 0.006) and the association stayed significant in a multivariate model (adjusted
OR = 0.80, 95% CI: 0.66-0.97; \( P = 0.019 \) adjustment for age, sex, smoking, drinking and family history of CHD (model 1). However, the association altered to null when BMI was introduced into the model (model 2). Subjects carried the G allele of rs4148152 had a decreased risk of CHD (AG + GG) (age and sex adjusted OR = 0.80, 95% CI: 0.68-0.95; \( P = 0.010 \)). The results remained significant in model 1 (adjusted OR = 0.80, 95% CI: 0.67-0.96; \( P = 0.015 \)) but changed to borderline significant in model 2 when BMI was introduced into the model (\( P = 0.062 \)). Further adjustment for the remaining traditional risk factors including total cholesterol, triglyceride, and past history of hypertension and diabetes got the similar null results (\( P = 0.306 \)).

Interactions between uric acid levels related SNPs and the traditional factors on CHD risk

We further investigated the associations between these two SNPs and CHD risk stratified by several traditional CHD risk factors such as sex (male/female), BMI (<24 and \( \geq 24 \) kg/m\(^2\)), smoking status (yes/no), alcohol consumption status (yes/no). Table 3 shows the ORs with 95% CIs adjusting for other risk factors except for the stratified factor. Among subjects who did not consume alcohol, the G allele of rs4148152 showed a moderate protective effect (adjusted OR = 0.79, 95% CI: 0.63-0.99; \( P = 0.038 \)), however, no significant interactions were observed between alcohol consumption and SNP of rs4148152 on CHD risk (\( P \) for interaction = 0.47). Similarly,

### Table 2 Adjusted Odds Ratios and 95% Confidence Intervals for CHD risk by different genotypes of the uric acid related SNPs in CHD cases and controls

| Genotypes | Genes | Location | Cases n (%) | Controls n (%) | Age- and sex-adjusted OR | Multivariate model 1* | Multivariate model 2† | Multivariate model 3‡ |
|-----------|-------|----------|-------------|-----------------|--------------------------|----------------------|----------------------|----------------------|
| CC        | rs11722228 | 564(50.2) | 586(52.7) | 1.00            | 1.00                     | 1.00                 | 1.00                 | 1.00                 |
| CT        | SLC2A9 | 472(42.0) | 449(40.3) | 1.09(0.92-1.30) | 0.319                 | 1.14(0.95-1.37)     | 0.175                | 1.08(0.89-1.31)     | 0.445                | 1.06(0.85-1.32)     | 0.611                |
| TT        | 4p16.1 | 87(7.8)   | 78(7.0)   | 1.16(0.83-1.60) | 0.388               | 1.19(0.84-1.69)     | 0.322                | 1.05(0.73-1.51)     | 0.801                | 1.27(0.84-1.93)     | 0.262                |
| CT+TT     |        | 559(49.8) | 527(47.3) | 1.15(0.96-1.37) | 0.268               | 1.15(0.96-1.37)     | 0.135                | 1.07(0.89-1.29)     | 0.452                | 1.09(0.88-1.35)     | 0.433                |
| AA        | rs4148152 | 533(47.4) | 463(42.0) | 1.00            | 1.00                     | 1.00                 | 1.00                 | 1.00                 |
| AG        | ABCG2  | 479(42.6) | 530(48.1) | 0.80(0.66-0.97) | 0.019               | 0.80(0.66-0.97)     | 0.019                | 0.85(0.70-1.03)     | 0.088                | 0.92(0.74-1.16)     | 0.483                |
| GG        | 4q22   | 112(10.0) | 109(9.9)  | 0.89(0.67-1.20) | 0.445               | 0.81(0.59-1.11)     | 0.192                | 0.81(0.58-1.12)     | 0.200                | 0.77(0.53-1.13)     | 0.182                |
| AG+GG     |        | 591(52.6) | 639(58.0) | 0.80(0.68-0.95) | 0.010               | 0.80(0.67-0.96)     | 0.015                | 0.84(0.70-1.01)     | 0.062                | 0.89(0.72-1.11)     | 0.306                |

* adjusted for age (continuous), sex (male, female), smoking (yes/no), drinking (yes/no) and family history of CHD (yes/no).
† adjusted for the same set of variables in model 1 plus BMI (continuous).
‡ adjusted for the same set of variables in model 2 plus total cholesterol (continuous), triglyceride (continuous), and the history of hypertension and diabetes (yes/no).

### Table 3 Stratified associations of SNPs rs11722228 and rs4148152 with CHD risk by CHD traditional risk factors

| Variables | Genotypes | CC | CT | TT | CT+TT | OR (95% CI) | \( P \) | AA | AG | GG | AG+GG | OR (95% CI) | \( P \) |
|-----------|-----------|----|----|----|-------|-------------|-------|----|----|----|-------|-------------|-------|
| Sex       | Male      | 1.00 | 1.07(0.86-1.33) | 1.14(0.75-1.71) | 1.08(0.87-1.33) | 0.62 | 1.00 | 0.83(0.67-1.03) | 0.83(0.58-1.21) | 0.83(0.67-1.02) | 0.86 |
|           | Female    | 1.00 | 1.19(0.78-1.81) | 0.77(0.34-1.75) | 1.12(0.75-1.68) | 1.00 | 0.82(0.54-1.26) | 0.71(0.34-1.46) | 0.80(0.53-1.20) | 0.99 |
| BMI (kg/m\(^2\)) | <24   | 1.00 | 0.97(0.74-1.27) | 1.14(0.68-1.91) | 1.00(0.77-1.29) | 0.55 | 1.00 | 0.82(0.62-1.07) | 0.84(0.54-1.32) | 0.82(0.64-1.07) | 0.77 |
|           | ≥24      | 1.00 | 1.22(0.92-1.60) | 1.01(0.61-1.68) | 1.18(0.91-1.54) | 1.00 | 0.86(0.65-1.14) | 0.76(0.48-1.22) | 0.84(0.65-1.10) | 0.99 |
| Smoking   | Yes       | 1.00 | 1.16(0.91-1.49) | 1.23(0.77-1.97) | 1.17(0.92-1.49) | 0.23 | 1.00 | 0.82(0.64-1.06) | 0.78(0.51-1.19) | 0.82(0.64-1.04) | 0.99 |
|           | No       | 1.00 | 1.01(0.74-1.37) | 0.85(0.48-1.53) | 0.98(0.73-1.32) | 1.00 | 0.87(0.64-1.19) | 0.86(0.51-1.45) | 0.87(0.65-1.17) | 0.77 |
| Drinking  | Yes       | 1.00 | 0.88(0.62-1.26) | 0.94(0.47-1.88) | 0.89(0.64-1.25) | 0.35 | 1.00 | 0.71(0.21-1.93) | 0.82(0.42-1.56) | 0.97(0.69-1.37) | 0.47 |
|           | No       | 1.00 | 1.19(0.94-1.50) | 1.09(0.71-1.67) | 1.17(0.94-1.47) | 1.00 | 0.79(0.63-1.00) | 0.78(0.53-1.14) | 0.79(0.63-0.99)* |

ORs and 95% CIs were obtained from logistic regression analyses with adjustment for age, sex, BMI, smoking, drinking and family history of CHD except for the stratified factor.

*, OR is significant at the 0.05 level.
\( P \), for interactions of CHD traditional risk factors with rs11722228 and rs4148152.
no interactions were observed for the two SNPs and other covariates on CHD risk.

**Discussion**

It still remains to be determined whether serum uric acid is an independent risk factor of CHD risk. As Mendelian randomization indicates, genetic variants could serve as an instrument to explore the causal associations between the biomarkers and the risk of diseases [13,42].

In the present study, we conducted a case–control study and selected two uric acid related SNPs rs11722228 (SLC2A9) [18,22,26,28,29] and rs4148152 (ABCG2) [12,30,31], which were found in our previous GWAS [32], to explore the potential contributing association of serum uric acid levels and CHD risk in a Chinese population. However, no association was found between the two uric acid related SNPs with CHD risk, indicating that there might not be causal association between them. Further studies are warranted to validate these results.

Previous GWASs have identified SLC2A9 and ABCG2 loci to be positively associated with serum uric acid levels and gout [13,22,43]. SLC2A9, also known as GLUT9 (glucose transporter type 9), is a glucose transporter and plays a significant role in maintaining glucose homeostasis. SLC2A9 is a causative gene for renal hyperuricemia and plays a significant role in urate reabsorption on renal proximal tubular cells [22,26]. ABCG2 is one of adenosine triphosphate (ATP) binding cassette family and expressed in kidney proximal tubule cellular membrane [8,44]. It transports purine nucleoside analogues, which resemble the molecular structure of uric acid and mediates urate excretion in the kidney.

Unfortunately, we did not find significant associations between the two variants and CHD risk. In addition, considering that the CHD traditional risk factors might modify these associations, we conducted stratification and interaction analysis but no significant interactions were found between these covariates and the two variants on CHD risk. The results indicated that the associations of the uric acid related variants with CHD risk were not modified by these CHD traditional risk factors and there might be no causal association between serum uric acid levels and CHD risk.

Several issues contributing to this null result should be noted. Firstly, only two independent uric acid related variants SNPs of rs11722228 and rs4148152 were selected to perform this association study and they explained only 1.03% and 1.09% of the total variation of serum uric acid levels, respectively [32]. Selection of more variants that explained more percentage of uric acid levels was warranted in further studies. Secondly, relatively small sample size in the present case–control study provided relatively weak power to examine this association. For example, our study had more than 80% power to examine variants with MAF = 0.3 and OR = 1.2 at two-side \( P < 0.05 \). However, the present study only had 32% power to detect variants with MAF = 0.3 and OR = 1.1 at \( P < 0.05 \) significant level. Further studies with larger sample size were needed to validate our results. Thirdly, the present study was conducted in Chinese Han population, further studies conducted in other populations were necessary.

**Conclusions**

In summary, this study did not find significant association of uric acid related SNP rs11722228 in SLC2A9 with the risk of CHD in a Chinese population. Subjects carried the G allele of rs4148152 in ABCG2 locus had decreased CHD risk, however, this association altered to borderline significant when BMI and other traditional risk factors were introduced into the multivariable model. No significant interactions between the two SNPs and CHD related risk factors were observed. Studies with larger sample size in other populations and genotyping more variants related to uric acid levels were warranted in future studies.

**Additional file**

**Additional file 1: Table S1.** The distribution of the covariates among different genotypes of rs11722228 and rs4148152 in controls.

**Abbreviations**

CHD: Coronary heart disease; SNP: Single nucleotide polymorphism; GWAS: Genome-wide association studies; OR: Odds ratio; CI: Confidence interval; EDTA: Ethylenediamine tetraacetic acid; BMI: Body mass index; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TC: Total cholesterol; TG: Triglyceride; SLC2A9: Solute carrier family 2, facilitated glucose transporter member 9; ABCG2: ATP-binding cassette, sub-family G, member 2.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

Conceived and designed the experiments: MH. Collected the samples: XH, LG, BL. Performed the experiments: XH, LG, BL, JW, YL, XD, JL, BY, GQ, JF. Analyzed the data: XH, LG, BL, JW, YL, and XD. Contributed reagents/materials/analysis tools: XH, XZ, TW and MH. Wrote the paper: XH and MH. All authors read and approved the final manuscript.

**Acknowledgements**

The authors would like to thank all the staff for assisting in collecting the clinic data in Tongji Hospital, Union Hospital and Wugang Hospital in Wuhan.
city, Hubei province, China. We also acknowledge all the volunteers for collecting questionnaire data and samples as well as all study subjects for participating in the present case–control study. The authors have no conflict of interest.

**Funding**

This work was supported by the grant from the National Natural Science Foundation (grant NSFC-81330042, NSFC-81172751 and NSFC-81230069) and the Program for the New Century Excellent Talents in University (NCET) for Meinan He.

Received: 19 August 2014 Accepted: 5 January 2015
Published online: 30 January 2015

**References**

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.
2. Wang F, Xu CQ, He Q, Cai JP, Li XC, Wang D, et al. Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet. 2011;43(4):345–9.
3. Gustavsson J, Mehlqvist K, Leander K, Strandhagen E, Björck JL, Thelle DS, et al. Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. Atherosclerosis. 2012;220(2):846–92.
4. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):23–22.
5. Katheresan S, Altschuler D, Anand S, Ardissino D, Asselta R, Ball SG, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41(3):334–41.
6. Fievet C, Nuttens MC, Ducimetiere P, Fruchtart JC, Bertrand M, Salomez JL. Relation of arteriographically defined coronary artery disease to serum lipoprotein particles mapped with monoclonal antibodies. Circulation. 1991;84(1):153–9.
7. Sundell J, Rajatink OT, Viikari J, Kantola I, Nuutila P, Knustt J. Both BMI and waist circumference are associated with coronary vasoactivity in overweight and obese men. Obes Facts. 2012;5(5):693–9.
8. Dehghan A, Kottgen A, Yang Q, Hwang S, Kao W, Rivadeneira F, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953–61.
9. Avram Z, Krishnan E. Hyperuricaemia–wherein nomenclature meets rheumatology. Rheumatology. 2008;47(7):960–4.
10. Tamba S, Nishiwa A, Funahashi T, Okuishi Y, Ogawa T, Noguchi M, et al. Relationship between the Serum Uric Acid Level, Visceral Fat Accumulation and Serum Adiponectin Concentration in Japanese Men. Intern Med. 2008;47(13):1175–80.
11. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287–93.
12. Stark K, Reinhard W, Grassl M, Erdmann J, Schunkert H, Ilg T, et al. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE. 2009;4(11):e7729.
13. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30–42.
14. Karbay M, Segal M, Afsar B, Kang DH, Rodríguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2009;99(11):759–66.
15. Kivity S, Kopol E, Maor E, Abu-Bachar F, Segov S, Sidi Y, et al. Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol. 2013;111(8):1146–51.
16. Nőpepega G, Braun S, King L, Fusaro M, Tada T, Cassese S, et al. Uric acid and prognosis in angiography-proven coronary artery disease. Eur J Clin Invest. 2013;43(3):256–66.
17. Jeemon P, Prabhakaran D. Does uric acid qualify as an independent risk factor for cardiovascular mortality? Clin Sci. 2013;124(4):255–7.
18. Wallace C, Newhouse SJ, Braun P, Zhang F, Tobin M, Fitchi M, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet. 2008;82(1):139–49.
19. Qi L, Parast L, Cai T, Powers C, Gervino EV, Hauser TH, et al. Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies. J Am Coll Cardiol. 2011;58(25):2675–82.
20. Chen LX, Lin MH, Lai HY, Hwang SJ, Chiou ST. Uric acid: a surrogate of insulin resistance in older women. Maturitas. 2008;59(1):55–61.
21. Moriatry JT, Folson AR, Ibarraeen C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARC) study. Ann Epidemiol. 2000;10(3):136–43.
22. Stark K, Reinhard W, Neureuther K, Wiedmann S, Sedlacek K, Baessler A, et al. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case–control study. PLoS ONE. 2008;3(4):e1948.
23. Qin L, Yang Z, Gu HK, Lu S, Shi Q, Xing Y, et al. Association between serum uric acid levels and cardiovascular disease in middle-aged and elderly Chinese individuals. BMC Cardiovasc Disor. 2014;14.
24. Chen KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chen-Shan Community Cardiovascular Cohort study. Atherosclerosis. 2005;183(1):147–55.
25. Yang Q, Kottgen A, Dehghan A, Smith AV, Gazer NL, Chen MH, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3(6):523–30.
26. Caufield MJ, Munroe PB, ONeill D, Witkowska K, Charchar FJ, Dobladen M, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10):e197.
27. Kolz M, Johnson T, Sanna S, Teumer A, Viatr V, Perola M, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5(6):e1000504.
28. Guan M, Zhou D, Ma W, Chen Y, Zhang J, Zou H. Association of an intrinsic SNP of SLC2A9 gene with serum uric acid levels in the Chinese male Han population by high-resolution melting method. Clin Rheumatol. 2011;30(1):29–35.
29. Reitsma PH, Reinhard W, Stark K, Neureuther K, Wiedmann S, Sedlacek K, et al. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case–control study. PLoS ONE. 2008;3(4):e1948.
30. Korns R, Zhang G, Sun G, Rao Indugula S, Cheng H, Hava-Augustyn D, et al. Genome-wide association of serum uric acid concentration: replication of sequence variants in an island population of the Adriatic coast of Croatia. Am J Hum Genet. 2012;96(2):121–7.
31. Gunjača G, Boban M, Pehlic M, Zemunik T, Budimir D, Kolz M, et al. Predictive value of 8 genetic loci for serum uric acid concentration. Croat Med J. 2010;51(1):23–9.
32. Yang B, Mo Z, Wu C, Yang H, Yang X, He Y, et al. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in adults. Atherosclerosis. 2014;235(1):233–38.
33. Palmer TM, Nordestgaard BG, Benn M, Tybjaerg-Hansen A, Davey Smith G, Lawlor DA, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013;347:f262.
34. Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27(9):2030–6.
35. Hamajima N, Okada R, Kawai S, Hishida A, Morita E, Yin G, et al. Significant association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case–control study. Atherosclerosis. 2008;203(4):e1948.
Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract. 1999;44(1):21–6.

39. Zhou L, Zhang X, He M, Cheng L, Chen Y, Hu FB, et al. Associations between single nucleotide polymorphisms on chromosome 9p21 and risk of coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol. 2008;28(11):2085–9.

40. Kim JY, Oh S, Chang MR, Cho YG, Park KH, Paek YJ, et al. Comparability and utility of body composition measurement vs. anthropometric measurement for assessing obesity related health risks in Korean men. Int J Clin Pract. 2013;67(1):73–80.

41. Li S, Zhao JH, Luan J, Langenberg C, Luben RN, Khaw KT, et al. Genetic predisposition to obesity leads to increased risk of type 2 diabetes. Diabetologia. 2011;54(4):276–82.

42. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res. 2007;16(4):309–30.

43. van der Harst P, Bakker SJ, de Boer RA, Wolffenbuttel BH, Johnson T, Caulfield M, et al. Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet. 2010;19(2):387–95.

44. Chen P, Zhao L, Zou P, Xu H, Lu A, Zhao P. The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature. BMC Cancer. 2012;12:383.